John Renger - 05 Aug 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role
Chief Scientific Officer
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
05 Aug 2022
Net transactions value
-$922,500
Form type
4
Filing time
09 Aug 2022, 21:23:30 UTC
Previous filing
22 Jul 2022
Next filing
12 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $70,000 +20,000 +740% $3.50* 22,704 05 Aug 2022 Direct F1
transaction CERE Common Stock Sale $650,000 -20,000 -88% $32.50 2,704 05 Aug 2022 Direct F1
transaction CERE Common Stock Options Exercise $35,000 +10,000 +370% $3.50* 12,704 08 Aug 2022 Direct F1
transaction CERE Common Stock Sale $377,500 -10,000 -79% $37.75 2,704 08 Aug 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -20,000 -14% $0.000000 119,770 05 Aug 2022 Common Stock 20,000 $3.50 Direct F1, F2
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -10,000 -8.3% $0.000000 109,770 08 Aug 2022 Common Stock 10,000 $3.50 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
F2 25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.